Quinn Wilojanapa

Associate

匹茲堡 + 1.412.394.7920

聯絡

*Share

Quinn Wilojanapa advises public and private companies on mergers and acquisitions and other strategic transactions. Her experience includes domestic and cross-border matters in a range of industries, including automotive, health care, consumer products, and technology. In addition, she has experience advising companies on corporate governance matters and shareholder engagement.

Recently, Quinn assisted with Bora Pharmaceuticals' acquisition of the GMP manufacturing operations of MacroGenics (Nasdaq: MGNX) for $122.5 million cash.

Quinn also maintains an active pro bono practice and is involved with the Pittsburgh Start Anew Clinic, which brings together community partners to provide job readiness, financial literacy, and other resources for survivors of human trafficking, domestic violence, and sexual abuse.

Quinn is author of "Do You Need This Drug? Television Ads Say 'Yes,' but the FCC Should Say 'No': A Blackout on Direct-to-Consumer Prescription Drug Advertisements," 86 U. Pitt. L. Rev. 851 (2025).

執業經驗

  • Bora Pharmaceuticals acquires MacroGenics, Inc.'s GMP manufacturing operationsJones Day represented Bora Pharmaceuticals Co., Ltd. in its acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc. (Nasdaq: MGNX) for $122.5 million cash.
  • Boviet Solar Technology sells U.S. PV module manufacturing and PV cell manufacturing assets to INOX Solar Americas for approximately $750 millionJones Day advised Boviet Solar USA Ltd, a leading solar technology company specializing in manufacturing top-performing Gamma Series™ Monofacial and Vega Series™ Bifacial PV modules, in the sale of its U.S.-based subsidiaries', Boviet Solar Technology (North Carolina) LLC, and Boviet Solar Cell Technology (North Carolina) LLC, assets to INOX Solar Americas, LLC, a U.S.-based renewable energy company backed by INOX Clean Energy Limited, for approximately $750 million.
    •

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.